Your browser doesn't support javascript.
loading
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
Lund, Lars H; Savarese, Gianluigi; Venkateshvaran, Ashwin; Benson, Lina; Lundberg, Anna; Donal, Erwan; Daubert, Jean-Claude; Oger, Emmanuel; Linde, Cecilia; Hage, Camilla.
Afiliación
  • Lund LH; Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Savarese G; Heart, Vascular and Neuro Theme, Department of Cardiology, Heart Failure Section, Karolinska University Hospital, Stockholm, SE-171 64, Sweden.
  • Venkateshvaran A; Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Benson L; Heart, Vascular and Neuro Theme, Department of Cardiology, Heart Failure Section, Karolinska University Hospital, Stockholm, SE-171 64, Sweden.
  • Lundberg A; Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Donal E; Heart, Vascular and Neuro Theme, Department of Cardiology, Heart Failure Section, Karolinska University Hospital, Stockholm, SE-171 64, Sweden.
  • Daubert JC; Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Oger E; Novartis Sverige, Kista, Sweden.
  • Linde C; University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.
  • Hage C; University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.
ESC Heart Fail ; 9(1): 164-177, 2022 02.
Article en En | MEDLINE | ID: mdl-34811954
AIMS: In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON-HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%). We assessed eligibility for sacubitril/valsartan based on four scenarios. METHODS AND RESULTS: Eligibility was assessed in the Karolinska-Rennes study (acute HFpEF, LVEF ≥ 45%, and N-terminal pro-B-type natriuretic peptide ≥300 pg/mL subsequently assessed as outpatients including echocardiography) in (i) a trial scenario (all trial criteria); (ii) a pragmatic scenario (selected trial criteria); (iii) LVEF below lower limit of normal range (<54% in women and <52% in men); and (iv) LVEF below mean of normal range (<64% in women and <62% in men). Among 425 patients [age 78 (72-83) years, 57% women, 28% LVEF ≤ 57% (median in PARAGON-HF), the trial scenario, identified 34% as eligible. Left atrial enlargement and/or left ventricular hypertrophy were present in 99%. Inclusion criteria not met were diuretic treatment and New York Heart Association class. Important exclusion criteria were estimated glomerular filtration rate <30 mL/min/1.73 m2 , haemoglobin <10 g/day, and cancer. In the pragmatic scenario, 63% were eligible. In LVEF below lower limit of normal range, 5.4% were eligible, and in LVEF below mean of normal range, 41% were eligible. In patients with LVEF ≤ 57%, eligibility was 42%, 69%, 21%, and 91% according to the trial scenario, pragmatic scenario, LVEF below lower limit of normal range, and LVEF below mean of normal range, respectively. CONCLUSIONS: In real-world HFpEF (LVEF ≥ 45%) with N-terminal pro-B-type natriuretic peptide and cardiac structure/function assessed, eligibility for sacubitril/valsartan was according to PARAGON-HF complete criteria 34%, pragmatic criteria 63%, LVEF below lower limit of normal range 5.4%, and LVEF below mean of normal range 41%. Cardiac structural impairment was almost ubiquitous. Ineligibility was more due to exclusion criteria than failing to meet inclusion criteria.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: ESC Heart Fail Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: ESC Heart Fail Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido